1-((4,5-bis(4-methoxyphenyl)-2-thiazoyl)carbonyl)-4-methylpiperazine,
FR 122047,
FR-122047,
FR 122047 hydrochloride,
130717-51-0,
FR 122047,
1-[[4,5-BIS(4-METHOXYPHENYL)-2-THIAZOLYL]CARBONYL]-4-METHYLPIPERAZINE HYDROCHLORIDE,
COX-1 Inhibitor, FR122047,
(4,5-Bis(4-methoxyphenyl)thiazol-2-yl)(4-methylpiperazin-1-yl)methanone hydrochloride,
[4,5-bis(4-methoxyphenyl)-1,3-thiazol-2-yl]-(4-methylpiperazin-1-yl)methanone hydrochloride,
1-[(4,5-Bis(4-methoxyphenyl-2-thiazoyl)carbonyl]-4-methylpiperazine, Hydrochloride,
4,5-Bis(4-methoxyphenyl-2-[(1-methylpiperazin-4-yl)carbonyl]thiazole, Hydrochloride,
SR-01000597794,
1-((4,5-Bis(4-methoxyphenyl)-2-thiazoyl)carbonyl)-4-methylpiperazine,
AC1L52EW,
SCHEMBL9548002,
IN1374,
AKOS022180740,
Piperazine, 1-((4,5-bis(4-methoxyphenyl)-2-thiazolyl)carbonyl)-4-methyl-, monohydrochloride,
DB-041983,
B6767,
FT-0643139,
J-005859,
SR-01000597794-1,
SR-01000597794-2,
FR 122047 hydrochloride, >=98% (HPLC), powder,
1-[(4,5-Bis(4-methoxyphenyl)-2-thiazoyl)carbonyl]-4-methylpiperazine hydrochloride,
Methanone, [4,5-bis(4-methoxyphenyl)-2-thiazolyl](4-methyl-1-piperazinyl)-, hydrochloride (1:1),
D09CMJ,
FR-122047,
CID196840,
FR122047,
C085131,